Obesity
Clinical Trial Update | Mesenteric defects closure in bariatric surgery cuts reoperation rate due to bowel obstruction
29 May, 2023 | 10:49h | UTCLong-term Safety and Efficacy of Closure of Mesenteric Defects in Laparoscopic Gastric Bypass Surgery: A Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
See also: Visual Abstract
Opinion Video | Questioning the reliability of nutrition science
23 May, 2023 | 13:02h | UTC
WHO advises not to use non-sugar sweeteners for weight control in newly released guideline
16 May, 2023 | 15:04h | UTCNews Release: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline – World Health Organization
WHO Guideline: Use of non-sugar sweeteners – World Health Organization
Meta-Analysis: Health effects of the use of non-sugar sweeteners – World Health Organization
Consensus | Addressing stigma/bias in diagnosing, managing obesity-based chronic disease, and evaluating determinants of severity
9 May, 2023 | 15:08h | UTC
RCT | Bariatric–metabolic surgery is more effective than lifestyle intervention plus best medical care in non-alcoholic steatohepatitis
24 Apr, 2023 | 14:03h | UTCNews Release: Surgery most effective treatment of metabolic liver disease – King’s College London
Commentary on Twitter
New @TheLancet – Verrastro et al – Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trialhttps://t.co/pCWahvbReQ#NASH #NAFLD #fattyliver #livertwitter pic.twitter.com/xNMsAskJF9
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 21, 2023
M-A | Positive end-expiratory pressure and postoperative complications in patients with obesity
18 Apr, 2023 | 13:11h | UTC
Report | The implications of defining obesity as a disease
18 Apr, 2023 | 12:55h | UTC
Commentary on Twitter
The implications of defining #obesity as a disease: a report from the ASO 2021 annual conference
"the goal is common: to provide a healthcare system that supports and protects the patients…and policies that reduce stigma and promote health equity"https://t.co/Iftxra5i2g pic.twitter.com/8luPJchn3x
— eClinicalMedicine – The Lancet Discovery Science (@eClinicalMed) April 11, 2023
Umbrella review unveils benefits of cutting free sugars to 6 teaspoons/day
10 Apr, 2023 | 14:00h | UTCDietary sugar consumption and health: umbrella review – The BMJ
News Release: Limit added sugar to six teaspoons a day to improve health, urge experts – BMJ Newsroom
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
5 Apr, 2023 | 12:50h | UTC
Cohort Study | Preoperative depression has minimal impact on 5-year bariatric surgery outcomes
4 Apr, 2023 | 13:23h | UTC
Assessing heart failure risk: waist-to-height ratio outperforms BMI in HFrEF patients
31 Mar, 2023 | 13:49h | UTCCommentary: Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives – TCTMD
M-A | The effect of curcumin supplementation on weight loss and anthropometric indices
27 Mar, 2023 | 13:04h | UTC
Phase 2 RCT | Semaglutide did not improve fibrosis in NASH-related cirrhosis
27 Mar, 2023 | 13:01h | UTCCommentary: Semaglutide Well-Tolerated, But Shows Lack of Improvement in Liver Fibrosis – HCP Live
Commentary on Twitter
New research – Loomba et al – Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialhttps://t.co/qkydKMpVfO#NASH #NAFLD #cirrhosis #gitwitter #livertwitter #medtwitter @DrLoomba pic.twitter.com/2A1dylSiq3
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) March 17, 2023
RCT | Effect of various dosing schedules on the pharmacokinetics of oral semaglutide
22 Mar, 2023 | 13:07h | UTC
RCT | Time-restricted eating not more effective than daily calorie restriction for managing nonalcoholic fatty liver disease
21 Mar, 2023 | 13:38h | UTCSummary: The TREATY-FLD randomized clinical trial investigated the effects of time-restricted eating (TRE) versus daily calorie restriction (DCR) on intrahepatic triglyceride (IHTG) content and metabolic risk factors in patients with obesity and nonalcoholic fatty liver disease (NAFLD).
Participants were randomly assigned to either TRE (eating only between 8:00 am and 4:00 pm) or DCR (habitual meal timing) and instructed to maintain a diet of 1500 to 1800 kcal/d for men and 1200 to 1500 kcal/d for women for 12 months.
The study found that the IHTG content was reduced by 6.9% in the TRE group and 7.9% in the DCR group after 12 months, a difference that was not statistically significant. Furthermore, TRE did not produce additional benefits for reducing body weight, liver stiffness, or metabolic risk factors compared with DCR.
The study supports that the main focus of a diet for managing NAFLD is caloric restriction, which can be achieved both with a TRE strategy or without a TRE strategy with similar results.
Commentary on Twitter
TREATY-FLD RCT found that time-restricted eating did not produce additional benefits for reducing intrahepatic triglyceride content, body fat and metabolic risk factors vs daily-calorie-restriction among adults with obesity and NAFLD. https://t.co/it2n4o9Th1
— JAMA Network Open (@JAMANetworkOpen) March 17, 2023
Review | Choosing the best endoscopic approach for post-bariatric surgical leaks and fistulas
20 Mar, 2023 | 13:23h | UTC
Associations of relative fat mass, a new index of adiposity, with type-2 diabetes in the general population
17 Mar, 2023 | 13:04h | UTC
M-A | Health effects of the time-restricted eating in adults with obesity
17 Mar, 2023 | 12:54h | UTCRelated:
Time-Restricted Eating: Integrating The What With The When – Advances in Nutrition
Cohort Study | Higher ultra-processed food consumption linked to increased cancer incidence and mortality
15 Mar, 2023 | 14:48h | UTCNews Release: Ultra-processed foods may be linked to increased risk of cancer – Imperial College London
Related:
Report | Economic impact of overweight and obesity to surpass $4 trillion by 2035
6 Mar, 2023 | 14:32h | UTCSummary:
A recent report from the World Obesity Federation has issued a warning that the number of people worldwide suffering from overweight or obesity could increase significantly by 2035, surpassing the 50% mark. The report, called the World Obesity Atlas 2023, also highlights the significant economic impact of this trend, estimating that the cost of overweight and obesity could reach $4.32tn annually by 2035, equivalent to almost 3% of the global GDP.
The report also identifies two groups that are particularly at risk: children and individuals from lower-income countries. Childhood obesity is a growing concern, as the report predicts it could double by 2035. Additionally, lower-income countries face a rapid increase in obesity prevalence, with nine out of 10 countries with the greatest expected increases in obesity coming from low or lower-middle income countries.
Report: World Obesity Atlas 2023
News release: Economic impact of overweight and obesity to surpass $4 trillion by 2035
Commentary: Report: Obesity could cost the world over $4 trillion a year by 2035 – STAT
Related:
Report: Tenfold increase in childhood and adolescent obesity in four decades
Global cost of obesity-related illness to hit $1.2tn a year from 2025
The Lancet Series: The Double Burden of Malnutrition
M-A | Sugar-sweetened beverage consumption and weight gain in children and adults
6 Mar, 2023 | 14:04h | UTCNews Release: More evidence that sugary drinks cause weight gain – University of Toronto
M-A | Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics
23 Feb, 2023 | 13:26h | UTCSummary: This study aimed to evaluate the mid- to long-term metabolic side effects of 31 antipsychotics in persons with schizophrenia by analyzing 137 eligible randomized controlled trials with 35,007 participants. The primary outcome was weight gain, with secondary outcomes including fasting glucose, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. The study found that antipsychotic drugs differ in their propensity to induce metabolic side effects. Chlorpromazine, clozapine, olanzapine, and zotepine produced the most weight gain. The confidence in the evidence ranged from low to moderate. The study suggests that differences in weight gain were more pronounced than previously published short-term data and that weight gain is most pronounced at the beginning of treatment and then remains stable.
Article: Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials – World Psychiatry (free for a limited period)
M-A | Sugar-sweetened beverage consumption and weight gain in children and adults
22 Feb, 2023 | 12:26h | UTC
Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019
22 Feb, 2023 | 12:17h | UTC
RCT | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease
20 Feb, 2023 | 12:27h | UTCSummary: The article reports on a randomized trial that compared the effects of alternate-day fasting (ADF) combined with exercise, fasting alone, or exercise alone in adults with obesity and non-alcoholic fatty liver disease (NAFLD). After three months, the combination of ADF and exercise significantly reduced intrahepatic triglyceride content, body weight, fat mass, waist circumference, and alanine transaminase levels compared to the control group. The intervention seems promising for patients with fatty liver disease who want to improve their health without using medications.
Article: Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial – Cell Metabolism (link to abstract – $ for full-text)
News Release: Alternate-day fasting could be a good option for patients with fatty liver disease – University of Illinois Chicago